Brief: Kura Oncology Doses First Patient In KOMET-008-008 Trial Of Ziftomenib In Combination With Standards Of Care, Including FLT3 Inhibitor, In Acute Myeloid Leukemia
26/02/2024 12:34
Feb 26 (Reuters) - Kura Oncology Inc KURA.O :
* KURA ONCOLOGY DOSES FIRST PATIENT IN KOMET-008 TRIAL OF
ZIFTOMENIB IN COMBINATION WITH STANDARDS OF CARE, INCLUDING FLT3
INHIBITOR, IN ACUTE MYELOID LEUKEMIA
Source text for Eikon: ID:nGNX1DMh9l
Further company coverage: KURA.O
((Reuters.Briefs@thomsonreuters.com;))